# Robert A. Burger

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/robert-a-burger/

## Facts

| Field | Value |
| --- | --- |
| Citations | 23,028 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 61 |
| i10-index | 147 |
| Last Known Institution | Mersana Therapeutics (United States) |
| OpenAlex ID | https://openalex.org/A5057221032 |
| ORCID iD | 0009-0005-2993-6616 |
| Works | 330 |

## Researcher papers

Showing 12 of 13.

- [Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer](https://scholariq.org/papers/intraperitoneal-cisplatin-and-paclitaxel-in-ovarian-cancer/)
- [Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/incorporation-of-bevacizumab-in-the-primary-treatment-of-ovarian-cancer/)
- [Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study](https://scholariq.org/papers/phase-iii-trial-of-carboplatin-and-paclitaxel-compared-with-cisplatin-and/)
- [Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study](https://scholariq.org/papers/phase-ii-trial-of-bevacizumab-in-persistent-or-recurrent-epithelial-ovarian/)
- [Inherited Mutations in Women With Ovarian Carcinoma](https://scholariq.org/papers/inherited-mutations-in-women-with-ovarian-carcinoma/)
- [Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer](https://scholariq.org/papers/phase-ii-study-of-bevacizumab-in-patients-with-platinum-resistant-ovarian-cancer/)
- [Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup](https://scholariq.org/papers/evaluation-of-new-platinum-based-treatment-regimens-in-advanced-stage-ovarian/)
- [Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)](https://scholariq.org/papers/bevacizumab-for-advanced-cervical-cancer-final-overall-survival-and-adverse/)
- [Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer](https://scholariq.org/papers/analysis-of-gene-expression-profiles-in-normal-and-neoplastic-ovarian-tissue/)
- [Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study](https://scholariq.org/papers/phase-iii-trial-of-doxorubicin-plus-cisplatin-with-or-without-paclitaxel-plus/)
- [Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer](https://scholariq.org/papers/final-overall-survival-of-a-randomized-trial-of-bevacizumab-for-primary/)
- [Ovarian Cancer, Version 3.2012](https://scholariq.org/papers/ovarian-cancer-version-3-2012/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Intraperitoneal and Appendiceal Malignancies](https://scholariq.org/topics/intraperitoneal-and-appendiceal-malignancies/)
- [Angiogenesis and VEGF in Cancer](https://scholariq.org/topics/angiogenesis-and-vegf-in-cancer/)

## Researcher university

- [Mersana Therapeutics (United States)](https://scholariq.org/institutions/mersana-therapeutics-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.